항말라리아약 시장 : 약제 클래스별, 투여 경로별, 유통 채널별, 지역별

Anti-Malarial Drugs Market is estimated to be valued at USD 1,081.2 Mn in 2025 and is expected to reach USD 1,471.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 4.5% from 2025 to 2032.

Plasmodium parasites, a protozoan parasite, are the cause of the widespread infectious disease malaria. A parasite enters the body through the bite of an infected female Anopheles mosquito, which then travels to the liver, where the parasite is produced. Human malaria are generally caused by five types of plasmodium parasites, including P. falciparum, P. malariae, P. ovale, P. vivax, and P.knowlesi. The most dangerous parasite species among these are P. falciparum and P. vivax, which are also the ones responsible for the majority of malaria deaths. Antimalarial drugs are used for the treatment and prevention of malaria infection. Most antimalarial drugs target the erythrocytic stage of malaria infection, which is the phase of infection that causes symptomatic illness. Early diagnosis and efficient treatment are crucial measures to control malaria. Different types of drugs such as quinine, chloroquine, mefloquine, proguanil, primaquine, and others are used in the treatment of malaria. Moreover, some combination drugs such as Pyrimethamine & sulfadoxine, Artemether & lumefantrine, and others are also prescribed for treating the disease.

Market Dynamics

The ongoing research and development for malarial treatment is expected to fuel growth of the market in the forecast period. Various drugs are undergoing the clinical trial for the malarial treatment, which is also expected to drive the market during the forecast period. Moreover, various pharmaceutical companies are actively participating in research and development activities, in order to develop novel drug entity for treatment of malaria. For instance, in November 2022, Novartis AG, a multinational pharmaceutical corporation and Medicines for Malaria Venture (MMV), a product development partnership in the field of antimalarial drug research and development announced decision to move to Phase 3 study for novel non-artemisinin combination to treat uncomplicated malaria. This novel combination also contains an optimized formulation of lumefantrine, which allows it to be given once daily versus the usual twice-daily administration. As the world faces emerging resistance to current malaria treatments, new medicines are needed to continue the fight toward elimination.

Key features of the study:

• This report provides in-depth analysis of the global anti-malarial drugs market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global anti-malarial drugs market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Ipca Laboratories Ltd., Zydus Group, Merck KGaA, Pfizer Inc., GSK plc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Alvizia Health Care, Bayer AG, and F. Hoffmann-La Roche Ltd.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global anti-malarial drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-malarial drugs market

Detailed Segmentation:

• Global Anti-malarial Drugs Market, By Drug Class:
  • Aminoquinolines
  • Quinoline-methanol (4-quinolinemethanols)
  • Cinchona Alkaloids
  • Biguanides
  • Sulfonamides and sulfones
  • Others
• Global Anti-malarial Drugs Market By Route of Administration:
  • Oral
  • Injectable
• Global Anti-malarial Drugs Market By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Anti-malarial Drugs Market, By Region:
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Ipca Laboratories Ltd.
  • Zydus Group
  • Merck KGaA
  • Pfizer Inc.
  • GSK plc.
  • Cipla Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • Alvizia Health Care
  • Bayer AG
  • Hoffmann-La Roche Ltd

Table of Contents

1. Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Anti-malarial Drugs Market, By Drug Class, 2020-2032 (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032(%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Aminoquinolines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Quinoline-methanol (4-quinolinemethanols)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Cinchona Alkaloids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Biguanides
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Sulfonamides and sulfones
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

5. Global Anti-malarial Drugs Market, By Route of Administration, 2020-2032 (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032(%)
  • Y-o-Y Growth Analysis, 2021-2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Global Anti-malarial Drugs Market, By Distribution Channel, 2020-2032 (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032(%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size, Volume and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size, Volume and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size, Volume and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Global Anti-malarial Drugs Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032(%)
  • Y-o-Y Growth Analysis, For Regions, 2021-2032
• North America
  • Market Size and Forecast, By Drug Class, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2032, (US$ Mn)
    • U.S.
    • Canada
• Latin America
  • Market Size and Forecast, By Drug Class, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2032, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Market Size and Forecast, By Drug Class, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2032, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Drug Class, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2032, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of APAC
• Middle East
  • Market Size and Forecast, By Drug Class, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2032, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Market Size and Forecast, By Drug Class, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Route of Administration, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2032, (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2032, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

• Company Profiles
  • Ipca Laboratories Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Zydus Group
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck KGaA
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GSK plc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Cipla Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Sun Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Alvizia Health Care
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • Bayer AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies
  • F. Hoffmann-La Roche Ltd
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Overview
    • Strategies

9. Section

• References
• Research Methodology
• About us and Sales Contact